Friday, November 03, 2017 1:12:20 PM
I fully expect results from the first of the 10 patients to be enrolled in the study will be starting to roll in. What will happen, if the news is good to spectacular, might well be very positive for share holders.
In the meantime we all can look forward to news regarding enrollment and iblue on the first patient.
Think about that guy/gal, if this works as advertised, see's the margins very clearly, the surgeon sees more cancer and gets all the cancer. Maybe they stop their cancer from coming back?
We'll be finding out soon enough. If it works as advertised, and remember all IME is doing is refining upgrading the technology from Lawrence Livermore. At Livermore US$4.5-5M was spent over 4 years, and numerous prototypes were built in the process of getting it right.
The way I see it IME's job is to prove, commercialize and sell what is, imo, essentially already a proven technology - it was used on 21 patients at Livermore/Davis and has been 'bench' tested at UofR.
Time will, as always provide clarity
FEATURED Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • Apr 25, 2024 8:52 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM